Potential biomarkers of major depression diagnosis and chronicity.
Adult
Algorithms
Area Under Curve
Biomarkers
/ metabolism
Brain-Derived Neurotrophic Factor
/ blood
C-Reactive Protein
/ biosynthesis
Case-Control Studies
Depressive Disorder, Major
/ blood
Female
Humans
Hydrocortisone
/ blood
Male
Middle Aged
Models, Theoretical
Prevalence
Psychiatric Status Rating Scales
Psychiatry
/ standards
Psychometrics
ROC Curve
Regression Analysis
Saliva
/ metabolism
Sleep
Time Factors
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
05
2021
accepted:
26
08
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Molecular biomarkers are promising tools to be routinely used in clinical psychiatry. Among psychiatric diseases, major depression disorder (MDD) has gotten attention due to its growing prevalence and morbidity. We tested some peripheral molecular parameters such as serum mature Brain-Derived Neurotrophic Factor (mBDNF), plasma C-Reactive Protein (CRP), serum cortisol (SC), and the salivary Cortisol Awakening Response (CAR), as well as the Pittsburgh sleep quality inventory (PSQI), as part of a multibiomarker panel for potential use in MDD diagnosis and evaluation of disease's chronicity using regression models, and ROC curve. For diagnosis model, two groups were analyzed: patients in the first episode of major depression (MD: n = 30) and a healthy control (CG: n = 32). None of those diagnosis models tested had greater power than Hamilton Depression Rating Scale-6. For MDD chronicity, a group of patients with treatment-resistant major depression (TRD: n = 28) was tested across the MD group. The best chronicity model (p < 0.05) that discriminated between MD and TRD included four parameters, namely PSQI, CAR, SC, and mBDNF (AUC ROC = 0.99), with 96% of sensitivity and 93% of specificity. These results indicate that changes in specific biomarkers (CAR, SC, mBDNF and PSQI) have potential on the evaluation of MDD chronicity, but not for its diagnosis. Therefore, these findings can contribute for further studies aiming the development of a stronger model to be commercially available and used in psychiatry clinical practice.
Sections du résumé
BACKGROUND
Molecular biomarkers are promising tools to be routinely used in clinical psychiatry. Among psychiatric diseases, major depression disorder (MDD) has gotten attention due to its growing prevalence and morbidity.
METHODS
We tested some peripheral molecular parameters such as serum mature Brain-Derived Neurotrophic Factor (mBDNF), plasma C-Reactive Protein (CRP), serum cortisol (SC), and the salivary Cortisol Awakening Response (CAR), as well as the Pittsburgh sleep quality inventory (PSQI), as part of a multibiomarker panel for potential use in MDD diagnosis and evaluation of disease's chronicity using regression models, and ROC curve.
RESULTS
For diagnosis model, two groups were analyzed: patients in the first episode of major depression (MD: n = 30) and a healthy control (CG: n = 32). None of those diagnosis models tested had greater power than Hamilton Depression Rating Scale-6. For MDD chronicity, a group of patients with treatment-resistant major depression (TRD: n = 28) was tested across the MD group. The best chronicity model (p < 0.05) that discriminated between MD and TRD included four parameters, namely PSQI, CAR, SC, and mBDNF (AUC ROC = 0.99), with 96% of sensitivity and 93% of specificity.
CONCLUSION
These results indicate that changes in specific biomarkers (CAR, SC, mBDNF and PSQI) have potential on the evaluation of MDD chronicity, but not for its diagnosis. Therefore, these findings can contribute for further studies aiming the development of a stronger model to be commercially available and used in psychiatry clinical practice.
Identifiants
pubmed: 34587177
doi: 10.1371/journal.pone.0257251
pii: PONE-D-21-17574
pmc: PMC8480905
doi:
Substances chimiques
Biomarkers
0
Brain-Derived Neurotrophic Factor
0
BDNF protein, human
7171WSG8A2
C-Reactive Protein
9007-41-4
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257251Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Psychiatry. 2015 Feb;76(2):e199-206
pubmed: 25742207
Br J Psychiatry. 2010 Nov;197(5):372-7
pubmed: 21037214
Compr Psychiatry. 2017 May;75:46-52
pubmed: 28301802
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Sleep. 2009 Feb;32(2):200-4
pubmed: 19238807
Psychopharmacology (Berl). 2006 Jul;186(4):601-11
pubmed: 16758243
Psychoneuroendocrinology. 2017 Jul;81:113-121
pubmed: 28441588
Psychoneuroendocrinology. 2013 Sep;38(9):1494-502
pubmed: 23313277
Int J Psychophysiol. 2010 Dec;78(3):201-8
pubmed: 20688111
J Affect Disord. 2019 Mar 1;246:42-51
pubmed: 30578945
J Affect Disord. 2011 Aug;132(3):396-400
pubmed: 21440308
Lancet. 2018 Nov 24;392(10161):2299-2312
pubmed: 30396512
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Transl Psychiatry. 2015 Sep 29;5:e649
pubmed: 26418277
J Psychosom Res. 2019 Oct;125:109796
pubmed: 31470255
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Expert Rev Proteomics. 2020 Apr;17(4):309-322
pubmed: 32516008
Front Behav Neurosci. 2020 Apr 28;14:44
pubmed: 32410966
Br J Psychiatry. 2014 Jul;205(1):29-35
pubmed: 24764546
Transl Psychiatry. 2016 Dec 13;6(12):e985
pubmed: 27959329
Psychiatry Res. 1984 Nov;13(3):221-9
pubmed: 6597461
Dialogues Clin Neurosci. 2014 Mar;16(1):63-73
pubmed: 24733971
Mol Psychiatry. 2011 Nov;16(11):1076-87
pubmed: 21709685
Psychoneuroendocrinology. 2003 Oct;28(7):916-31
pubmed: 12892658
Front Psychol. 2021 Aug 05;12:641779
pubmed: 34421705
Psychiatry Res. 2018 Dec;270:246-252
pubmed: 30269042
Psychiatry Res. 2011 Apr 30;186(2-3):427-30
pubmed: 20826006
Psychiatry Investig. 2010 Dec;7(4):231-5
pubmed: 21253405
Psychoneuroendocrinology. 2010 Jul;35(6):921-31
pubmed: 20079576
Psychiatry Res. 2016 May 30;239:85-91
pubmed: 27137966
J Affect Disord. 2014 Aug;164:118-22
pubmed: 24856564
Eur Arch Psychiatry Clin Neurosci. 2019 Oct;269(7):823-832
pubmed: 30392042
Psychosom Med. 2003 May-Jun;65(3):347-56
pubmed: 12764206
PLoS One. 2020 Oct 16;15(10):e0240668
pubmed: 33064754
Noro Psikiyatr Ars. 2018 May 28;55(3):280-290
pubmed: 30224877
Mol Psychiatry. 2013 Mar;18(3):332-9
pubmed: 22158016
J Affect Disord. 2014 Jan;152-154:534-7
pubmed: 24161452
Biol Psychiatry. 2008 Sep 15;64(6):527-32
pubmed: 18571629
Am J Psychiatry. 2004 Dec;161(12):2163-77
pubmed: 15569884
Biol Psychiatry. 2007 Sep 1;62(5):479-86
pubmed: 17481591
J Neuroendocrinol. 2007 Mar;19(3):213-26
pubmed: 17280595
PLoS One. 2010 Feb 11;5(2):e9166
pubmed: 20161799
J Nerv Ment Dis. 1999 Jun;187(6):360-8
pubmed: 10379723
Psychol Bull. 2017 Aug;143(8):783-822
pubmed: 28447828
Neuropsychiatr Dis Treat. 2017 May 10;13:1245-1262
pubmed: 28546750
J Psychiatr Res. 2003 Jan-Feb;37(1):9-15
pubmed: 12482465
Int Arch Med. 2010 Jan 12;3:1
pubmed: 20150988
J Nerv Ment Dis. 2019 Apr;207(4):271-276
pubmed: 30844940
Acta Psychiatr Scand. 1975 Mar;51(3):161-70
pubmed: 1136841
Metabolism. 2015 Mar;64(3 Suppl 1):S2-S10
pubmed: 25496803
Dialogues Clin Neurosci. 2008;10(3):329-36
pubmed: 18979946
Front Psychol. 2019 Jun 04;10:1234
pubmed: 31231276
J Pediatr (Rio J). 2009 Jan-Feb;85(1):42-7
pubmed: 19198734
Med J Armed Forces India. 2023 Jul-Aug;79(4):451-457
pubmed: 37441286
Psychother Psychosom. 2020;89(3):133-150
pubmed: 32289809
Ann Med. 2016;48(1-2):42-51
pubmed: 26758201
BMC Genomics. 2016 Aug 23;17:669
pubmed: 27549765
Neurosci Bull. 2021 Jun;37(6):863-880
pubmed: 33582959
Metabolism. 2015 Mar;64(3 Suppl 1):S11-5
pubmed: 25467847
Psychiatry Clin Neurosci. 2003 Dec;57(6):575-9
pubmed: 14629705
Psychopharmacology (Berl). 2016 May;233(9):1669-78
pubmed: 25877654
Neuropsychopharmacology. 2011 Nov;36(12):2375-94
pubmed: 21814182
Neurosci Biobehav Rev. 2016 May;64:101-33
pubmed: 26906761
Mol Psychiatry. 2020 Feb;25(2):321-338
pubmed: 31745238
Psychol Res Behav Manag. 2018 Oct 16;11:495-502
pubmed: 30425596
Transl Psychiatry. 2021 Feb 4;11(1):97
pubmed: 33542178
Rev Chilena Infectol. 2012 Apr;29(2):138-41
pubmed: 22689026
J Psychiatr Res. 2008 Jun;42(7):521-5
pubmed: 17585940
J Psychopharmacol. 2020 Oct;34(10):1125-1133
pubmed: 32648790
Ther Adv Psychopharmacol. 2020 Sep 01;10:2045125320937921
pubmed: 32953039
Mol Psychiatry. 2009 Feb;14(2):156-74
pubmed: 18301394
Sleep Med Rev. 2018 Jun;39:187-194
pubmed: 29126903
Sleep Med. 2011 Jan;12(1):70-5
pubmed: 21145786
J Cell Mol Med. 2019 Apr;23(4):2324-2332
pubmed: 30734486
PLoS One. 2018 Jun 1;13(6):e0197267
pubmed: 29856741
Mol Psychiatry. 2014 Feb;19(2):151-2
pubmed: 23399916